Abstract 4860
Background
BC patients who have evidence of bone metastases should be treated with BMAs in order to reduce skeletal related events. ONJ is a serious complication associated the use of BMAs. In this large population-based study we evaluate the patterns of use of BMAs and ONJ rates in a cohort of older BC patients.
Methods
Patients diagnosed with de novo metastatic BC between 2007-2013 were identified in the SEER-Medicare database. We identified the presence of bone metastases using specific PEDSF variables and claims. All patients were required to receive systemic anticancer therapy within one year of diagnosis. HCPCS codes were used to identify the use of BMAs within 1 year of cancer diagnosis, ONJ was identified using an established ICD-9 codes. Descriptive statistics and regression models were used.
Results
A total of 1,528 patients were included. The median age of the cohort was 74 yo. Within one year of diagnosis of bone metastases 71.1% of the patients received BMAs (68% bisphosphonates, 27% denosumab, 5% both). Older patients (OR = 0.64; 95%CI 0.46-0.89), those with more comorbidities (OR = 0.61; 95%CI 0.43-0.85) or with full/partial state buy-in (OR = 0.65; 95%CI 0.49-0.87) -surrogate for poverty- were less likely to receive BMAs. Nineteen cases of ONJ were identified, all of them occurred among BMAs-treated patients (1.7%), the 2-year and 4-year cumulative rates were 1.4% and 4.0%, respectively. Similar rates of ONJ were observed between patients treated with bisphosphonates and denosumab. Median duration of BMA therapy among patients who developed ONJ was 20 months (IQR 10-43). No clinical predictors of ONJ were identified.
Conclusions
In this large, nationally-representative cohort, the majority of the BC patients with evidence of bone metastases received treatment with BMA according to current guidelines. Similar rates of ONJ were observed among bisphosphonates and denosumab users. ONJ occurred in approximately 2% of this SEER-Medicare population of patients with BC and bone metastases treated with BMA. Our findings are of significant value since they reflect the patterns of care and complications associated with these commonly used agents in the general population.
Clinical trial identification
Legal entity responsible for the study
Mariana Cgavez Mac Gregor.
Funding
CERCIT, Sudan G. Komen.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract